细胞株开发市场、机会、成长动力、产业趋势分析与预测，2024-2032

在产品发布和技术创新激增的推动下，细胞株开发市场预计 2024 年至 2032 年复合年增长率将达到 10.3%。

生技公司和研究人员正在利用 CRISPR 基因编辑、自动化和高通量筛选等尖端技术，旨在打造高效可靠的细胞系。这些技术进步不仅加速了细胞系的开发，也提高了细胞系在药物发现、治疗生产和生物医学研究等多种应用中的精确度。例如，2023 年 6 月，JSR Life Sciences 旗下的 KBI Biopharma 推出了 KBI PURE 平台。这种创新的微生物细胞株开发平台有望提高微生物表现效率，特别是对于生物製药生产。

整个市场分为产品和服务、来源、细胞株、应用、最终用途和地区。

就来源而言，在生物製药生产需求不断增长的推动下，细胞株开发市场中的哺乳动物细分市场将在 2032 年显着增长。研究人员依靠哺乳动物细胞，同时采用基因工程技术来提高生产力和稳定性，从而产生重要的治疗性蛋白质和抗体。此外，随着这些进步，哺乳动物细胞係正在产生高品质的治疗方法，满足对复杂医疗日益增长的需求。

从应用来看，药物发现领域的细胞株开发产业价值预计将在 2024 年至 2032 年期间上升。透过建构模拟人类生理学的专门细胞系，科学家们对药物交互作用和作用有了更深入的了解。细胞株开发的不断完善为更准确的药物测试铺平了道路，最终加速了新药物的发现。

从地区来看，在再生医学日益受到关注的推动下，亚太地区细胞株开发市场规模预计将在 2024 年至 2032 年间呈现强劲成长。研究人员和生物技术公司正在利用先进的细胞株技术来开发修復或替换受损组织和器官的疗法。细胞株开发的持续发展也将支持再生医学的进步，为治疗该地区的各种医疗状况带来新的希望。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 全球疫苗产量不断成长
    • 全球癌症盛行率不断上升
    • 细胞株开发的技术创新
    • 不断发展的生物技术产业
  • 产业陷阱与挑战
    • 复杂的监管环境
    • 干细胞研究相关问题
• 成长潜力分析
• 未来市场趋势
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品和服务分类，2021 - 2032 年

• 主要趋势
• 试剂和介质
• 装置
  • 孵化器
  • 离心机
  • 生物反应器
  • 仓储设备
  • 显微镜
  • 电穿孔器
  • 萤光活化细胞分选
  • 其他设备
• 配件及消耗品
• 服务

第 6 章：市场估计与预测：按来源划分，2021 - 2032 年

• 主要趋势
• 哺乳动物
• 非哺乳动物
  • 昆虫
  • 两栖类

第 7 章：市场估计与预测：按细胞株，2021 - 2032

• 主要趋势
• 重组
• 杂交瘤
• 连续性细胞系
• 原代细胞系

第 8 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 生物生产
• 药物发现
• 毒性测试
• 组织工程
• 研究应用

第 9 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 製药和生物技术公司
• 学术及研究机构
• 合约研究组织 (CRO)

第 10 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 11 章：公司简介

• Advanced Instruments, LLC
• Aragen Life Sciences Ltd.
• ASIMOV
• Cytiva (Danaher Corporation)
• Eurofins Scientific
• Fyonibio
• GenScript Biotech
• Lonza Group AG
• Novartis AG
• ProBioGen
• PromoCell
• Sartorius AG
• Sigma Aldrich (Merck KGaA)
• Thermo Fisher Scientific Inc.
• WuXi AppTec

Cell Line Development Market is projected to record a 10.3% CAGR from 2024 to 2032, driven by a surge in product launches and technological innovations.

Biotech firms and researchers are harnessing cutting-edge techniques like CRISPR gene editing, automation, and high-throughput screening, aiming to craft cell lines that are both efficient and reliable. These technological strides are not only accelerating the development of cell lines but also bolstering their precision for diverse applications, spanning drug discovery, therapeutic production, and biomedical research. For example, in June 2023, KBI Biopharma, under the umbrella of JSR Life Sciences, unveiled the KBI PURE platform. This innovative microbial cell line development platform is poised to enhance microbial expression efficiencies, especially for biopharmaceutical production.

The overall market is segregated into products and services, source, cell line, application, end-use, and region.

In terms of source, the mammalian segment in the cell line development market will experience significant growth by 2032 driven by an escalating demand in biopharmaceutical production. Researchers are counting on mammalian cells while employing genetic engineering techniques to boost productivity and stability, thereby producing vital therapeutic proteins and antibodies. Moreover, with these advancements, mammalian-derived cell lines are generating high-quality therapeutics, catering to the rising appetite for sophisticated medical treatments.

By application, the cell line development industry value from the drug discovery segment is projected to rise from 2024 to 2032. This can be attributed to the escalating need for precise and efficient therapeutic testing models. By crafting specialized cell lines that emulate human physiology, scientists are gaining deeper insights into drug interactions and effects. This ongoing refinement in cell line development is paving the way for more accurate drug testing, ultimately expediting the discovery of new medications.

Regionally, the Asia Pacific cell line development market size is projected to exhibit robust growth between 2024 and 2032, fueled by the growing focus on regenerative medicine. Researchers and biotech companies are leveraging advanced cell line technologies to develop therapies for repairing or replacing damaged tissues and organs. The ongoing evolution in cell line development will also support the advancement of regenerative medicine to offer new hope for treating a wide range of medical conditions across the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing vaccine production worldwide
    • 3.2.1.2 Increasing prevalence of cancer across globe
    • 3.2.1.3 Technological innovation in cell line development
    • 3.2.1.4 Growing biotechnology industry
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Complex regulatory landscape
    • 3.2.2.2 Issues related to stem cell research
• 3.3 Growth potential analysis
• 3.4 Future market trends
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Products and Services, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Reagents and media
• 5.3 Equipment
  • 5.3.1 Incubator
  • 5.3.2 Centrifuges
  • 5.3.3 Bioreactors
  • 5.3.4 Storage equipment
  • 5.3.5 Microscopes
  • 5.3.6 Electroporators
  • 5.3.7 Fluorescence-activated cell sorting
  • 5.3.8 Other equipment
• 5.4 Accessories and consumables
• 5.5 Services

Chapter 6 Market Estimates and Forecast, By Source, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Mammalian
• 6.3 Non-mammalian
  • 6.3.1 Insects
  • 6.3.2 Amphibians

Chapter 7 Market Estimates and Forecast, By Cell Line, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Recombinant
• 7.3 Hybridomas
• 7.4 Continuous cell lines
• 7.5 Primary cell lines

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Bioproduction
• 8.3 Drug discovery
• 8.4 Toxicity testing
• 8.5 Tissue engineering
• 8.6 Research applications

Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Pharmaceutical and biotechnology companies
• 9.3 Academic and research institutes
• 9.4 Contract research organizations (CROs)

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 The Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Advanced Instruments, LLC
• 11.2 Aragen Life Sciences Ltd.
• 11.3 ASIMOV
• 11.4 Cytiva (Danaher Corporation)
• 11.5 Eurofins Scientific
• 11.6 Fyonibio
• 11.7 GenScript Biotech
• 11.8 Lonza Group AG
• 11.9 Novartis AG
• 11.10 ProBioGen
• 11.11 PromoCell
• 11.12 Sartorius AG
• 11.13 Sigma Aldrich (Merck KGaA)
• 11.14 Thermo Fisher Scientific Inc.
• 11.15 WuXi AppTec